MOTS-c and Exercise: Is It Really an Exercise Mimetic?

If you have seen MOTS-c described as "exercise in a vial", you have probably wondered how much of that is backed by data. The short answer: MOTS-c and exercise are clearly linked in the lab, but the link runs mostly through mouse studies and a single small human trial. By the end of this article you will know what was actually measured, in whom, and what remains unproven.

Why MOTS-c Gets Called an "Exercise Mimetic"

An exercise mimetic is a compound that triggers some of the same molecular signals as physical activity. Researchers are interested in them for conditions where people cannot train, such as frailty or chronic illness.

MOTS-c earned the label for three reasons:

• It activates AMPK, the same energy-sensing enzyme that switches on when muscles work hard (Lee et al., 2015).
• Its levels rise in human muscle and blood during exercise (Reynolds et al., 2021).
• Giving it to mice improved their running performance (Reynolds et al., 2021).

Each of these points is real, but each also comes with limits, covered below.

A Peptide Made by Your Mitochondria

Most proteins are encoded in the DNA of the cell nucleus. MOTS-c is different: its 16-amino-acid sequence sits inside the 12S rRNA gene of mitochondrial DNA, the small genome of the cell's power plants. It was identified in 2015 by a group at the University of Southern California (Lee et al., 2015).

That origin matters for the exercise story. Mitochondria are the part of the cell that adapts most to endurance training, so a signal produced by them is a natural candidate for linking muscle work to whole-body metabolism.

How MOTS-c Connects to Exercise Signalling

The AMPK pathway

In cell and mouse experiments, MOTS-c slowed the folate cycle and the purine-building pathway attached to it. This caused AICAR, an intermediate of that pathway, to build up, which in turn activated AMPK (Lee et al., 2015).

AMPK acts like a fuel gauge. When cellular energy runs low, as during a hard workout, it pushes muscle to take up more glucose and burn more fat. Mimicking that switch is the core of the "exercise mimetic" idea.

A stress signal that reaches the nucleus

A 2018 study added a second layer. Under metabolic stress, such as glucose restriction in cultured cells, MOTS-c moved from the cytoplasm into the nucleus. There it influenced genes involved in antioxidant and stress responses, partly through the transcription factor NRF2 (Kim et al., 2018).

In plain terms, the mitochondria appear to send a message to the nucleus saying "energy is tight, adapt". Exercise creates exactly this kind of temporary stress, which is one reason researchers see MOTS-c as part of the training response.

What Happens to MOTS-c Levels When Humans Exercise?

The key human data come from one study of 10 healthy, sedentary young men who performed a session on a stationary bike (Reynolds et al., 2021). The researchers measured MOTS-c in muscle and blood:

• In skeletal muscle: levels were about 11.9 times higher after exercise than before.
• In blood during exercise: levels rose about 1.6-fold.
• In blood after exercise: levels were still about 1.5-fold higher, then returned to baseline after four hours of rest.

This shows that exercise raises MOTS-c in people. It does not show that the rise causes any of the benefits of training, and the sample was small and limited to young men.

Mouse Studies on Endurance and Physical Decline

The same 2021 paper tested MOTS-c treatment in mice of different ages (Reynolds et al., 2021):

• Young, middle-aged and old mice given MOTS-c performed better on physical tests than untreated mice.
• Late-life treatment: mice that started intermittent injections three times a week at 23.5 months of age, roughly equivalent to old age in humans, showed better physical capacity and healthspan measures.
• Muscle cells in culture adapted better to metabolic stress when MOTS-c was present.

Earlier work in mice found that MOTS-c prevented diet-induced obesity and age-related insulin resistance (Lee et al., 2015). Muscle was identified as its main target tissue, which fits the exercise link.

Does Physical Activity Interact With MOTS-c Genetics?

A mitochondrial DNA variant called m.1382A>C, found in Northeast Asian populations, changes one amino acid of MOTS-c (K14Q). In a meta-analysis of three cohorts with 27,527 people, men carrying the variant had a higher prevalence of type 2 diabetes. In one Japanese cohort, this association appeared only in the least physically active men (Zempo et al., 2021).

This is observational data, so it cannot prove cause and effect. Still, it hints that activity levels and MOTS-c biology may interact in humans. In the same paper, the K14Q form of the peptide was less effective than the usual form in mice and cells.

MOTS-c, Metabolism and Blood Levels in People

Other human studies have looked at circulating MOTS-c rather than exercise:

• In 20 people, plasma MOTS-c was similar in lean and obese participants but was associated with insulin sensitivity only in the lean group (Cataldo et al., 2018).
• In 225 people, serum MOTS-c was lower in those with type 2 diabetes and fell with age, HbA1c and glucose (Ramanjaneya et al., 2019).

These are associations from small, single-time-point studies.

Has MOTS-c Been Tested in a Clinical Trial?

MOTS-c itself has not been studied in a published controlled human trial. The closest is CB4211, a modified MOTS-c analogue tested in a phase 1a/1b study with 88 participants (ClinicalTrials.gov, NCT03998514). In its phase 1b stage, 20 adults with obesity and fatty liver disease received the analogue or placebo daily for four weeks. The developer reported larger falls in the liver enzymes ALT and AST and in glucose than with placebo, with mainly mild injection-site reactions (CohBar, 2021). These results were company-reported and concern the analogue, not MOTS-c. The trial did not measure exercise performance.

MOTS-c and Exercise: Evidence Summary

Can MOTS-c Replace Training?

No study supports that. The human evidence shows only that exercise raises MOTS-c, not that MOTS-c reproduces the effects of exercise. Training also changes the heart, blood vessels, bones, brain and many other systems through signals that have nothing to do with MOTS-c.

The fairer description is that MOTS-c is one of many messengers involved in how muscle responds to exercise, and a research tool for studying that response.

Status in Sport and in the EU

For athletes in Germany, France, Italy, Spain or anywhere else under the World Anti-Doping Code, the position is clear. The 2026 WADA Prohibited List names MOTS-c under S4.4.1 (metabolic modulators) as an AMPK activator, alongside AICAR, and bans it both in and out of competition (WADA, 2026). National anti-doping agencies apply the same list.

MOTS-c is not authorised as a medicine in the EU, and no marketing application for it has been made public.

Frequently Asked Questions

Is MOTS-c an exercise mimetic?

It has been described that way because it activates AMPK and improved physical performance in mice. Whether it mimics exercise in humans has not been tested.

Does exercise increase MOTS-c?

Yes, in one study of 10 young men, muscle levels rose about 11.9-fold and blood levels about 1.6-fold with a cycling session.

Has MOTS-c improved endurance in humans?

No published human study has tested this. Performance improvements were seen in mice.

Is MOTS-c banned in sport?

Yes. It is listed under S4.4.1 of the WADA Prohibited List and is banned at all times.

Is the evidence mostly from animals?

Yes. Most mechanism and performance data come from cells and mice. Human data are limited to small observational studies, one exercise study and one trial of an analogue.

Final Thoughts

MOTS-c sits at an interesting crossroads between mitochondria, muscle and metabolism. Exercise raises its levels in humans, and in mice it activates AMPK and improves physical performance across ages. Yet the "exercise mimetic" label goes beyond the evidence: there are no controlled human trials of MOTS-c, and the data so far come mainly from animal and cell studies.

Next step: if you follow this field, watch for peer-reviewed human trials that measure performance or metabolic outcomes directly. Those will decide whether the label holds up.

Buy MOTS-c at Peptides EU

If you have reviewed the research and want MOTS-c for your own laboratory work, you can buy MOTS-c from Peptides EU.

Disclaimer

For research purposes only. Not medical advice. Consult a qualified professional. This article is for informational and educational purposes and reflects published research and regulatory information as of October 2026. Most findings described here come from animal and cell studies and may not apply to humans. MOTS-c is not authorised as a medicine, and nothing in this article has been evaluated by any regulatory authority. It should not be used to make decisions about diagnosis or treatment. Always speak with a qualified healthcare professional before starting any medication or health-related product.

References

• Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
• Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. doi:10.1038/s41467-020-20790-0
• Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008
• Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. doi:10.18632/aging.202529
• Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. Journal of Investigative Medicine. 2018;66(6):1019-1022. doi:10.1136/jim-2017-000681
• Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Frontiers in Endocrinology. 2019;10:331. doi:10.3389/fendo.2019.00331
• ClinicalTrials.gov. A Phase 1a/1b study of CB4211 (NCT03998514). clinicaltrials.gov
• CohBar, Inc. Topline results from the Phase 1a/1b study of CB4211. Press release, 10 August 2021 (SEC Form 8-K exhibit). sec.gov
• World Anti-Doping Agency. The 2026 Prohibited List. wada-ama.org